Clinical trial
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome; a Phase Ib-IIa Placebo-controlled Clinical Trial and Associated Mechanistic Studies
NCT04496960 is registered in ClinicalTrials.gov with National Institute of Dental and Craniofacial Research (NIDCR) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome; a Phase Ib-IIa Placebo-controlled Clinical Trial and Associated Mechanistic Studies
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- May 18, 2021
- Completion date
- September 22, 2026
- Enrollment
- 23 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.